The Effect Of Injecting siRNA Angiotensinogen On Wistar Strain Male Rats (Rattus Norvegicus) Blood Pressure

Abstract

High blood pressure, or hypertension, is a major risk factor for various cardiovascular diseases and chronic heart failure. Although medication can help lower blood pressure, it often has side effects. Gene therapy using small interfering RNA (siRNA) has been proposed as a potential solution to regulate blood pressure by targeting proteins involved in blood pressure regulation, such as angiotensinogen. A study on rats aimed to determine the effect of intravenously administered siRNA-angiotensinogen on blood pressure. The siRNA was designed using sequence-angiotensinogen mRNA Rattus norvegicus obtained from NCBI and was given to normal and spontaneously hypertensive rats (SHR) in different doses. Blood pressure measurements were taken at various intervals after treatment, and angiotensinogen protein was isolated from blood plasma for analysis. The results showed that siRNA treatment decreased blood pressure in both normal rats and SHR, while the placebo group did not experience a decrease in blood pressure. The reduction in blood pressure in the SHR group ranged from 21-53% (SBP) and 17-58% (DBP) compared to the control group. Gene therapy using siRNA has the potential to provide long-lasting and highly specific control of blood pressure, and further research is needed to explore its effectiveness and safety in humans.